Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Real-World study tracks CLL patients on acalabrutinib

NCT ID NCT05645172

Knowledge-focused Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study watches 137 adults with chronic lymphocytic leukemia (CLL) who are already prescribed acalabrutinib by their doctors. Researchers will track how many patients are still taking the drug after 1 and 2 years. No new treatments or changes are made—just observation of real-world use in Germany.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

137 people

The number who actually took part.

Started

Dec 2022

Expected to finish

Oct 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

CLL patients with a newly initiated acalabrutinib treatment in routine clinical practice are planned to be included from approximately 75 sites in Germany over a recruitment period of 16 months.

Ages

18 to 99 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥ 18 years * Diagnosis of CLL * Ability to understand the study concept and to regularly complete patient questionnaires from physical, mental, and linguistic perspectives * Decision to start therapy with acalabrutinib according to the current SmPC. For previously untreated patients as continuous therapy with or without obinutuzumab. OR For patients with at least one prior CLL therapy as continuous monotherapy. * Provision of signed informed consent form Exclusion Criteria: * Current or planned participation in an interventional clinical trial * Contraindications to treatment with acalabrutinib according to the current SmPC * Pregnancy or breast feeding * Disease progression on prior BTKi therapy * Start of acalabrutinib therapy more than 28 days prior to enrolment

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic lymphocytic leukaemia (CLL) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

B-cell chronic lymphocytic leukemia Leukemia, B-Cell

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Chronic lymphocytic leukaemia (CLL)

Contacts and locations

Locations

  • Research Site

    D Ren, Germany, 52353, Germany

  • Research Site

    Herrsching am Ammersee, Germany, 82211, Germany

  • Research Site

    L Rrach, Germany, 79539, Germany

  • Research Site

    M Nchen, Germany, 80804, Germany

  • Research Site

    M Nchen, Germany, 81377, Germany

  • Research Site

    N Rnberg, Germany, 90449, Germany

  • Research Site

    Neustadt Am R Benberge, Germany, 31535, Germany

  • Research Site

    Saarbr Cken, Germany, 66113, Germany

  • Research Site

    Sindelfinden, Germany, 71065, Germany

  • Research Site

    W Rselen, Germany, 52146, Germany

  • Research Site

    Amberg, 92224, Germany

  • Research Site

    Aschaffenburg, 63739, Germany

  • Research Site

    Augsburg, 86150, Germany

  • Research Site

    Bad Homburg, 61352, Germany

  • Research Site

    Bad Liebenwerda, 04924, Germany

  • Research Site

    Bautzen, 02625, Germany

  • Research Site

    Berlin, 10117, Germany

  • Research Site

    Berlin, 13055, Germany

  • Research Site

    Berlin, 13156, Germany

  • Research Site

    Bonn, 53115, Germany

  • Research Site

    Dachau, 85221, Germany

  • Research Site

    Delitzsch, 04509, Germany

  • Research Site

    Dessau, 06487, Germany

  • Research Site

    Dortmund, 44263, Germany

  • Research Site

    Erfurt, 99084, Germany

  • Research Site

    Erfurt, 99085, Germany

  • Research Site

    Essen, 45136, Germany

  • Research Site

    Frankfurt am Main, 60596, Germany

  • Research Site

    Frankfurt am Main, 65929, Germany

  • Research Site

    Garbsen, 30823, Germany

  • Research Site

    Halle, 06110, Germany

  • Research Site

    Hanover, 30161, Germany

  • Research Site

    Hanover, 30625, Germany

  • Research Site

    Heide, 25746, Germany

  • Research Site

    Herten, 45699, Germany

  • Research Site

    Hof, 04509, Germany

  • Research Site

    Kulmbach, 95326, Germany

  • Research Site

    Laatzen, 30880, Germany

  • Research Site

    Landshut, 72764, Germany

  • Research Site

    Lebach, 66822, Germany

  • Research Site

    Leipzig, 04103, Germany

  • Research Site

    Leipzig, 04289, Germany

  • Research Site

    Moers, 47441, Germany

  • Research Site

    Naunhof, 04683, Germany

  • Research Site

    Oldenburg, 26121, Germany

  • Research Site

    Paderborn, 33098, Germany

  • Research Site

    Pasing, 81281, Germany

  • Research Site

    Pirna, 01796, Germany

  • Research Site

    Porta Westfalica, 32457, Germany

  • Research Site

    Potsdam, 14482, Germany

  • Research Site

    Remscheid, 42859, Germany

  • Research Site

    Reutlingen, 72764, Germany

  • Research Site

    Riesa, 01589, Germany

  • Research Site

    Saalfeld, 07318, Germany

  • Research Site

    Schkeuditz, 04435, Germany

  • Research Site

    Schorndorf, 73614, Germany

  • Research Site

    Siegburg, 53721, Germany

  • Research Site

    Straubing, 94315, Germany

  • Research Site

    Twistringen, 27239, Germany

  • Research Site

    Weiden, 92637, Germany

  • Research Site

    Zittau, '02763, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.